| Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. | |
| | |
MedLine Citation:
|
PMID: 21907000 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Monoclonal antibodies (mAbs) are in widespread use for the treatment of cancer. Their success as cancer therapeutics relies substantially on their ability to engage the immune system. Specifically, Fc-receptor-expressing immune cells mediate the killing of tumor cells by mAbs. Stimulation of these immune effector cells might therefore represent a promising strategy to enhance the therapeutic potential of mAbs. For instance, stimulation of natural killer cells, γδ T cells, macrophages, or dendritic cells can be used to enhance antibody-dependent cellular cytotoxicity, phagocytosis or even tumor vaccine effects. Here, we review several ways to improve the antitumor efficacy of mAbs by combining them with therapies that are directed against immune effector cells. |
| | |
Authors:
|
Roch Houot; Holbrook E Kohrt; Aurélien Marabelle; Ronald Levy |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-8 |
Journal Detail:
|
Title: Trends in immunology Volume: - ISSN: 1471-4981 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-12 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100966032 Medline TA: Trends Immunol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Ltd. All rights reserved. |
Affiliation:
|
CHU Rennes, Service Hématologie Clinique, F-35033 Rennes, France; INSERM, U917, F-35043 Rennes, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Risk Factors and Management Approach for Deep Sternal Wound Infection After Cardiac Surgery at a Ter...
Next Document: The emerging role of p53 in stem cells.